Low dose naltrexone (LDN) does appear to reduce certain markers of inflammation, and early clinical evidence shows meaningful symptom improvement in several inflammatory conditions. But the research is still limited to small trials and pilot studies, so calling it a proven anti-inflammatory treatment would be premature. Here’s what the science actually shows so far.
How LDN Differs From Standard Naltrexone
Naltrexone was originally approved to treat opioid and alcohol addiction at doses of 50 mg per day. Low dose naltrexone uses a fraction of that, typically between 1 and 4.5 mg per day. At these much smaller doses, the drug appears to interact with the immune system in ways that the full dose does not. The most commonly prescribed LDN dose is 4.5 mg daily, though effective doses in chronic pain studies have ranged from 0.1 to 6 mg per day. Finding the right dose appears to be highly individual.
How LDN Affects Inflammatory Pathways
LDN’s anti-inflammatory effects center on its interaction with toll-like receptors, which are sensors on immune cells that trigger inflammation when they detect threats. Lab research shows that naltrexone inhibits the production of two key inflammatory signaling molecules: IL-6 and TNF-alpha. These are the same molecules that drive symptoms in many chronic inflammatory conditions, from joint pain to fatigue.
Interestingly, the mechanism is more nuanced than initially thought. Early research suggested LDN worked primarily by blocking TLR4, a specific receptor involved in broad immune activation. But a study published in Frontiers in Immunology found no effect on inflammation triggered through TLR4. Instead, naltrexone suppressed inflammatory signaling through TLR7/8 and TLR9, which are receptors located inside immune cells rather than on their surface. It reduced IL-6 production by monocytes (a common type of white blood cell) and TNF-alpha production by a specialized group of immune cells called plasmacytoid dendritic cells. The practical takeaway: LDN does dampen inflammation, but through more specific pathways than a blanket immune suppression.
Evidence in Fibromyalgia
Fibromyalgia is one of the most studied conditions for LDN, largely because of work done at Stanford. A pilot study found that LDN reduced fibromyalgia symptoms by more than 30% compared to placebo. Patients also showed improved pain thresholds for both mechanical pressure and heat, suggesting the drug was changing how their nervous system processed pain signals rather than just masking discomfort. These are small studies, but the consistency of the improvement across multiple measures is notable.
Evidence in Crohn’s Disease
For Crohn’s disease, a condition driven by gut inflammation, the results are more mixed. In a randomized controlled trial of adults with moderate to severe Crohn’s, 30% of patients taking 4.5 mg of LDN daily achieved clinical remission at 12 weeks, compared to 18% on placebo. That difference was not statistically significant, meaning it could have been due to chance. A more encouraging signal came from endoscopic data: 22% of LDN patients showed actual healing of their intestinal lining, compared to 0% on placebo. A small pediatric trial found 25% of children on LDN achieved remission compared to none on placebo. These numbers are promising but come from very small sample sizes, so they need to be confirmed in larger trials.
Evidence in Multiple Sclerosis
A pilot trial of 80 people with MS found that LDN significantly improved mental health quality of life scores, pain, and cognitive function (specifically, perceived mental sharpness). Physical disability scores did not change, which makes sense given that LDN would not be expected to reverse existing nerve damage. The improvements were modest but statistically significant, and the drug was well tolerated with no serious adverse events. The high dropout rate in this study, with only 60 of 80 participants completing the trial, limits the strength of the conclusions.
Evidence in Long COVID Fatigue
One of the more recent areas of interest is post-COVID fatigue and brain fog, conditions thought to involve lingering inflammation. A pilot study of 36 patients with persistent moderate to severe fatigue after COVID treated them with LDN (4.5 mg daily) combined with a supplement called NAD+. After 12 weeks, fatigue scores dropped from 25.9 to 17.4 on a standardized scale, and overall quality of life scores improved significantly. About 52% of participants were classified as responders. The most dramatic improvements were in physical limitations, energy levels, and pain. Because this study combined LDN with another treatment and had no placebo group, it’s impossible to say exactly how much LDN contributed on its own. A separate study of 38 people with long COVID symptoms treated with lower-dose LDN (1 to 3 mg daily) also found improvements in energy, pain, concentration, and sleep after two months.
How Long It Takes to Work
If you’re considering LDN, patience matters. In a case series tracking chronic pain patients, most people (72%) didn’t notice improvement until somewhere between one and three months after starting treatment. Another 12% took longer than three months. Only a minority felt benefits in the first few weeks. This slow onset likely reflects the time needed for the drug’s immune-modulating effects to accumulate and translate into symptom changes. Clinicians who prescribe LDN typically advise completing at least a full course before deciding whether it’s working.
Side Effects
LDN is generally well tolerated, though side effects are not uncommon. In a retrospective study of 93 chronic pain patients, about half reported at least one side effect. The most frequent was nausea, affecting roughly 19% of patients. Fatigue occurred in about 8%, and vivid dreams and insomnia each affected around 6%. Headaches were reported by about 5%. No serious adverse events have been reported across the clinical trials conducted so far. Most side effects are mild and tend to settle over time, particularly sleep-related ones.
One important practical note: because naltrexone blocks opioid receptors, it can interact with opioid pain medications. Earlier concerns suggested patients needed a washout period off opioids before starting LDN, but more recent evidence indicates that very low and low doses can be tolerated alongside opioid therapy if introduced carefully. Dose adjustments can manage any withdrawal-like symptoms that arise.
The Bottom Line on Inflammation
The lab evidence clearly shows that naltrexone reduces production of key inflammatory molecules in human immune cells. The clinical evidence, while still early, consistently points in the same direction: modest but real improvements in conditions driven by inflammation, including fibromyalgia, Crohn’s disease, MS, and post-COVID fatigue. The limitation is that nearly all the human trials have been small, often involving fewer than 40 participants, and some lack placebo controls. LDN is not yet an established anti-inflammatory treatment in the way that conventional medications are, but the signal across multiple conditions is consistent enough that larger trials are underway. For people with inflammatory conditions who haven’t responded well to standard treatments, the risk-benefit profile of LDN looks favorable given its mild side effect profile.